<div id="readability-page-1"><div><p>PROCEPT BioRobotics (PRCT) is back in the spotlight after updated American Urological Association guidelines strengthened support for its Aquablation therapy in treating benign prostatic hyperplasia, including patients with larger prostates.</p> <p>See our latest analysis for PROCEPT BioRobotics.</p> <p>The latest guideline update and recent Q1 report come against a mixed trading backdrop, with a 7 day share price return of 2.83% but a 1 year total shareholder return that has declined 55.02%. This suggests recent momentum is improving from a weaker longer term trend.</p> <p>If you are looking beyond PROCEPT BioRobotics for other robotics focused opportunities in healthcare and automation, now could be a good time to review 29 robotics and automation stocks</p> <p>With PROCEPT BioRobotics stock down 55.02% over the past year and trading about 16.6% below the average analyst price target, investors now face a key question: is this a genuine opportunity, or are expectations for future growth already fully reflected in the current price?</p> <h2>Most Popular Narrative: 14.2% Undervalued</h2> <p>The most followed narrative pegs PROCEPT BioRobotics fair value at $30.44 per share, above the last close of $26.12, and links that gap to procedure adoption and margin expansion.</p> <blockquote> <p><em>The ongoing expansion of HYDROS robotic system placements into both high-volume and mid/lower volume hospitals, in conjunction with rising utilization by a growing base of engaged surgeons, indicates significant untapped market potential that could support recurring consumables revenue growth and eventual expansion in gross and operating margins.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Investors may be curious what kind of revenue runway and margin shift could support that higher fair value, and over what time frame those changes might be reflected in the models.</p> <p><strong>Result: Fair Value of $30.44 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, that upside story relies heavily on Aquablation, so any slower than expected surgeon adoption or regulatory and reimbursement setbacks could quickly undercut the bullish narrative.</p> <p>Find out about the key risks to this PROCEPT BioRobotics narrative.</p> <h2>Next Steps</h2> <p>Mixed signals on upside and risk so far? Take a closer look at the underlying data and form your own view by weighing the 1 key reward and 2 important warning signs.</p> <h2>Looking for more investment ideas?</h2> <p>If PROCEPT BioRobotics has your attention, do not stop there; broaden your watchlist with other focused stock ideas that match your risk and return goals.</p> <ul> <li>Hunt for potential bargains by scanning companies that combine quality fundamentals with attractive pricing using the 50 high quality undervalued stocks.</li> <li>Prioritize resilience by checking out stocks with stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (45 results).</li> <li>Spot opportunities that others may be overlooking by reviewing a screener containing 22 high quality undiscovered gems.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

PRCT

<p>PROCEPT BioRobotics (PRCT) gains attention as updated AUA guidelines boost support for its Aquablation therapy. Despite a recent 2.83% share price increase, the stock has declined 55.02% over the past year. Analysts value the stock at $30.44, suggesting it is undervalued compared to its last close of $26.12. The potential for revenue growth hinges on surgeon adoption and market expansion, but risks remain. Investors are encouraged to explore other robotics and automation stocks for opportunities.</p>

Simplywall

PROCEPT BioRobotics

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

SPDR S&P Health Equip

ALPS Medical Breakthrough

iShares US Medical Devices

Invesco Biotechnology & Genome ETF

A Look At PROCEPT BioRobotics (PRCT) Valuation As AUA Guideline Update Expands Aquablation Opportunity